Mirum Pharmaceuticals (STU:08D) Total Liabilities: €560.9 Mil (As of Mar. 2026)


STU:08D Mirum Pharmaceuticals Inc STU:08D
51 GF Score
Price €109.30
GF Value €67.40
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Mirum Pharmaceuticals Total Liabilities?

Mirum Pharmaceuticals STU:08D -2.10% 51 Total Liabilities is €560.9 Mil as of Mar. 2026. GuruFocus rates STU:08D with a GF Score™ of 51/100 and a GF Value™ of €67.40 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Mirum Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 was €560.9 Mil.

Mirum Pharmaceuticals's quarterly Total Liabilities increased from Sep. 2025 (€420.10 Mil) to Dec. 2025 (€451.02 Mil) and increased from Dec. 2025 (€451.02 Mil) to Mar. 2026 (€560.89 Mil).

Mirum Pharmaceuticals's annual Total Liabilities increased from Dec. 2023 (€364.92 Mil) to Dec. 2024 (€425.08 Mil) and increased from Dec. 2024 (€425.08 Mil) to Dec. 2025 (€451.02 Mil).

Mirum Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for Mirum Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mirum Pharmaceuticals Total Liabilities Chart

Mirum Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 154.38 199.06 364.92 425.08 451.02

Mirum Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 422.72 408.07 420.10 451.02 560.89
STU:08D
51GF Score
Mirum Pharmaceuticals Inc STU:08D
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mirum Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Mirum Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=175.752+(270.985+4.28
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=451.0

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=719.762-268.745
=451.0

Mirum Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=235.993+(278.033+46.859
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=560.9

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=770.642-209.757
=560.9

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €560.9 Mil mean?
Mirum Pharmaceuticals (STU:08D) has a Total Liabilities of €560.9 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Mirum Pharmaceuticals and its competitors.
Is Mirum Pharmaceuticals' Total Liabilities too high?
Mirum Pharmaceuticals' current Total Liabilities is €560.9 Mil. Overall, Mirum Pharmaceuticals has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mirum Pharmaceuticals' Total Liabilities compare to RYTM and SYRE?
Mirum Pharmaceuticals' Total Liabilities of €560.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Mirum Pharmaceuticals and its competitors. Mirum Pharmaceuticals's current Total Liabilities is €560.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mirum Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Mirum Pharmaceuticals (STU:08D) is currently considered Significantly Overvalued. The stock's GF Value™ is €67.40, compared to a current price of €109.30 — trading 62.2% above its estimated fair value. The current Total Liabilities is €560.9 Mil. Mirum Pharmaceuticals' overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Mirum Pharmaceuticals (STU:08D), the current Total Liabilities is €560.9 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mirum Pharmaceuticals (STU:08D) Overvalued in 2026?

Based on GuruFocus' analysis, Mirum Pharmaceuticals stock appears to be overvalued. The current stock price of €109.30 is trading 62.2% above its estimated GF Value™ of €67.40. GuruFocus considers Mirum Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for STU:08D:

  • Total Liabilities: €560.9 Mil
  • GF Value™: €67.40 vs. price of €109.30 (62.2% above fair value)
  • GF Score™: 51/100 with 6 warning signs

No single metric tells the full story. See the STU:08D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mirum Pharmaceuticals Business Description

Other Exchanges MIRM:USA
Address 989 East Hillsdale Boulevard, Suite 300, Foster City, CA, USA, 94404
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
51GF Score

Get the complete analysis for STU:08D

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€109.30
Price
€67.40
GF Value